Renalytix PLC
renalytix.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q1 FY2025 10-Q, filed Nov 19, 2024. Its latest SEC filing is a SCHEDULE 13D/A from Feb 23, 2026.
10-Q for Q1 FY2025, filed Nov 19, 2024
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Provides doctors and health systems with a blood-based test that uses an artificial intelligence algorithm to assess the risk of kidney function decline in adults with diabetes and early-stage kidney disease.
10-K for FY2024, filed Sep 30, 2024
Who Were Their Customers?
Renalytix works with healthcare systems and insurance payors to offer KidneyIntelX testing, using a direct-to-doctor sales approach; it also provides analytical services to pharmaceutical customers.
10-K for FY2024, filed Sep 30, 2024We are deploying KidneyIntelX to patient populations with DKD on a regional basis through partnerships with healthcare systems and…View ↗
During this past year, Management has completed a series of operational restructurings that has resulted in new sales leadership…View ↗
Pharmaceutical services revenue is generated from the provision of analytical services to customers. Contracts with customers generally…View ↗
How Were They Changing?
Test authorization
The earlier report described KidneyIntelX as a laboratory-developed test; the latest describes kidneyintelX.dkd as authorized by the U.S. Food and Drug Administration, with customers transitioned from the earlier version.
20-F for FY2021, filed Oct 21, 2021 10-K for FY2024, filed Sep 30, 2024Renalytix is focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs.…View ↗
Loading...
